Congress Asset Management Co. Sells 429,504 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Congress Asset Management Co. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 99.0% during the 4th quarter, HoldingsChannel reports. The fund owned 4,361 shares of the medical research company’s stock after selling 429,504 shares during the quarter. Congress Asset Management Co.’s holdings in Charles River Laboratories International were worth $805,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Wellington Management Group LLP grew its position in shares of Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after purchasing an additional 3,738,018 shares in the last quarter. State Street Corp increased its stake in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after acquiring an additional 47,221 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Charles River Laboratories International by 6.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock valued at $101,483,000 after acquiring an additional 32,311 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after purchasing an additional 85,759 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CRL shares. UBS Group reaffirmed a “neutral” rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Evercore ISI upped their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Morgan Stanley dropped their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Finally, CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and an average target price of $197.64.

Charles River Laboratories International Trading Up 1.7 %

Shares of NYSE CRL opened at $154.63 on Wednesday. The stock has a market cap of $7.91 billion, a P/E ratio of 19.35, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. The firm has a 50 day moving average price of $174.59 and a two-hundred day moving average price of $189.16. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $275.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).